| scholarly article | Q13442814 |
| P2093 | author name string | David W Powell | |
| Michael J Ryan | |||
| Michelle T Barati | |||
| Erin B Taylor | |||
| Hannah R Turbeville | |||
| P2860 | cites work | Mechanisms of Kidney Injury in Lupus Nephritis - the Role of Anti-dsDNA Antibodies | Q26781272 |
| Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry | Q30663976 | ||
| Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma | Q33379044 | ||
| Anti-dsDNA antibodies promote initiation, and acquired loss of renal Dnase1 promotes progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice | Q33521279 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation | Q34267100 | ||
| The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus | Q34464260 | ||
| Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus | Q34604744 | ||
| Bortezomib, a proteasome inhibitor, attenuates angiotensin II-induced hypertension and aortic remodeling in rats | Q35036537 | ||
| Preventing autoimmunity protects against the development of hypertension and renal injury | Q35159241 | ||
| A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis | Q35174510 | ||
| Blood pressure in a hypertensive mouse model of SLE is not salt-sensitive | Q35543439 | ||
| Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus | Q35543444 | ||
| Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. | Q35682855 | ||
| Differences in the occurrence of hypertension among (NZB X NZW)F1, MRL-lpr, and BXSB mice with lupus nephritis. | Q35857947 | ||
| Humoral immunity due to long-lived plasma cells. | Q52040025 | ||
| Lifetime of plasma cells in the bone marrow. | Q52042101 | ||
| The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. | Q53675215 | ||
| Dysregulation of the Circulating and Tissue-Based Renin-Angiotensin System in Preeclampsia | Q56981959 | ||
| Raised serum IgG levels in hypertension. | Q64903796 | ||
| Autoantibodies in Untreated and Treated Essential Hypertension: Relationship to Histocompatability Leucocyte Antigen-B15 and Vascular Complications | Q66996308 | ||
| Hypertension and renal disease in systemic lupus erythematosus | Q67806367 | ||
| Increased secretion of immunoglobulins in malignant hypertension | Q69490195 | ||
| Increased serum IgG levels in essential hypertension | Q70673965 | ||
| Autoantibodies and vascular events in essential hypertension: a five-year longitudinal study | Q70767241 | ||
| Anti-endothelial cell antibodies in sera of patients with autoimmune diseases: comparison between ELISA and FACS analysis | Q71997934 | ||
| The dissociation of arterial hypertension and lupus glomerulonephritis in systemic lupus erythematosus | Q72414305 | ||
| Antiendothelial cell antibodies in lupus: correlations with renal injury and circulating markers of endothelial damage | Q72668651 | ||
| B cells process and present lupus autoantigens that initiate autoimmune T cell responses | Q72756556 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice | Q74432712 | ||
| Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells | Q74460576 | ||
| Treatment with a laminin-derived peptide suppresses lupus nephritis | Q81322423 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus | Q83619645 | ||
| The role of angiotensin II type 1 receptor-activating antibodies in patients with lupus nephritis | Q86051142 | ||
| Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients | Q35928031 | ||
| Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice | Q35931319 | ||
| AT1 receptor agonistic antibodies, hypertension, and preeclampsia | Q35941020 | ||
| Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial | Q35993027 | ||
| Subtle renal injury is likely a common mechanism for salt-sensitive essential hypertension. | Q36012008 | ||
| Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions | Q36026798 | ||
| Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction | Q36229028 | ||
| Resistance of long-lived lymphocytes and plasma cells in rat lymph nodes to treatment with prednisone, cyclophosphamide, 6-mercaptopurine, and actinomycin D. | Q36268554 | ||
| Induction of autoreactive B cells allows priming of autoreactive T cells | Q36361095 | ||
| A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus | Q36369955 | ||
| Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice | Q36399066 | ||
| Antiendothelial cell antibodies in vasculitis and connective tissue disease | Q36434227 | ||
| Plasma cell purification from murine bone marrow using a two-step isolation approach | Q36498779 | ||
| Autoantibodies in rheumatoid arthritis: a review | Q36634532 | ||
| Oxidative stress promotes hypertension and albuminuria during the autoimmune disease systemic lupus erythematosus | Q36932669 | ||
| Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation | Q37087713 | ||
| Hypertension in rheumatoid arthritis. | Q37158219 | ||
| Hypertension in an experimental model of systemic lupus erythematosus occurs independently of the renal nerves | Q37234995 | ||
| Updating on the pathogenesis of systemic lupus erythematosus | Q37791687 | ||
| Autoantibodies in lupus: culprits or passive bystanders? | Q37951283 | ||
| B cell biology: implications for treatment of systemic lupus erythematosus | Q38095860 | ||
| The efficacy of novel B cell biologics as the future of SLE treatment: a review | Q38242432 | ||
| A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients | Q38275587 | ||
| Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study | Q38466691 | ||
| Plasma cells as an innovative target in autoimmune disease with renal manifestations | Q38753491 | ||
| Immunosuppression With Mycophenolate Mofetil Attenuates Hypertension in an Experimental Model of Autoimmune Disease | Q38938727 | ||
| Obligatory Role for B Cells in the Development of Angiotensin II-Dependent Hypertension | Q38966025 | ||
| Cardiovascular involvement in systemic lupus erythematosus | Q39706504 | ||
| Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. | Q40169580 | ||
| Antiendothelial cell antibodies mediate enhanced leukocyte adhesion to cytokine-activated endothelial cells through a novel mechanism requiring cooperation between Fc{gamma}RIIa and CXCR1/2. | Q40179910 | ||
| Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells | Q40310345 | ||
| Autoantibodies in Untreated and Treated Essential Hypertension. I | Q40670361 | ||
| Vascular stiffness in women with systemic lupus erythematosus | Q43576508 | ||
| Bortezomib attenuates murine collagen-induced arthritis | Q43914924 | ||
| Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension | Q44162378 | ||
| Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular system. | Q46034044 | ||
| The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis | Q46549173 | ||
| Persistent hypertension in lupus nephritis and the associated risk factors. | Q50616527 | ||
| Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus. | Q51786420 | ||
| Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. | Q51819270 | ||
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2018-01-29 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease |
| Q64232439 | Autoimmune Disease-Associated Hypertension |
| Q64280996 | Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus |
| Q57772657 | Hypertension: a new treatment for an old disease? Targeting the immune system |
| Q67405024 | Immune mechanisms of hypertension. |
| Q64283956 | Mechanisms of hypertension in autoimmune rheumatic diseases |
| Q90159347 | Temporal Hemodynamic Changes in a Female Mouse Model of Systemic Lupus Erythematosus |
Search more.